Copyright
©The Author(s) 2015.
World J Diabetes. Sep 10, 2015; 6(11): 1186-1197
Published online Sep 10, 2015. doi: 10.4239/wjd.v6.i11.1186
Published online Sep 10, 2015. doi: 10.4239/wjd.v6.i11.1186
Figure 2 Glucagon-like peptide-1 and blood pressure.
Summary of changes in systolic blood pressure (SBP) after the 6-mo study end point in subjects with type 2 diabetes treated with exenatide vs placebo. Data are presented as differences between baseline-to-end point in the least squares (mean ± SE). Adapt from Okerson et al[29]. GLP-1: Glucagon-like peptide-1.
- Citation: Sanchez RA, Sanabria H, Santos CL, Ramirez AJ. Incretins and selective renal sodium-glucose co-transporter 2 inhibitors in hypertension and coronary heart disease. World J Diabetes 2015; 6(11): 1186-1197
- URL: https://www.wjgnet.com/1948-9358/full/v6/i11/1186.htm
- DOI: https://dx.doi.org/10.4239/wjd.v6.i11.1186